Long-Term Suppression of HIV Infection: Benefits and Limitations of Current Treatment Options

Journal of the Association of Nurses in AIDS Care

Volumn 18, Issue 1 SUPPL., 2007, Pages

  Sension, Michael G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG COMBINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 33846574256     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jana.2006.11.012     Document Type: Article

References (25)

1. Berger D.S., Bellos N., Farthing C., Stryker R., Colson A.E., Pierone G., et al. December. TMC114/r in 3-class-experienced patients: 24-wk primary safety analysis of the Power 2 study (C202) (2005), 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC Abstract H-1094
2. Boehringer Ingelheim Pharmaceuticals, Inc. Aptivus prescribing information (2006), Author, Ridgefield, CT
3. Bozzette S.A., Joyce G., McCaffrey D.F., Leibowitz A.A., Morton S.C., Berry S.H., et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. New England Journal of Medicine 344 (2001) 817-823
4. Bristol-Myers Squibb Company. Sustiva prescribing information (2005), Author, Princeton, NJ
5. Department of Health and Human Services. (2006, October). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Retrieved December 11, 2006, from http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Gui delines&Search=OfT&GuidelineID=7&ClassID=1.
6. Grinsztejn B., Arasteh K., Clotet B., Cunha C.A., Goffard J.C., Spinosa-Guzman S., et al. July. TMC114/r is well tolerated in 3-class-experienced patients: Week 24 primary safety analysis of POWER 1 (TMC114-C213) (2005), Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil Abstract WePeLB6.201
7. Hammer S.M., Saag M.S., Schechter M., Montaner J.S.G., Schooley R.T., Jacobsen D.M., et al. Treatment for adult HIV infection 2006 Recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 296 (2006) 827-843
8. Hicks C.B., Cahn P., Cooper D.A., Walmsley S.L., Katlama C., Clotet B., et al. Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. The Lancet 368 (2006) 466-475
9. Johnson M., Grinsztejn B., Rodriguez C., Coco J., DeJesus E., Lazzarin A., et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19 (2005) 685-694
10. Johnson M., Grinsztejn B., Rodriguez C., Coco J., DeJesus E., Lazzarin A., et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 20 (2006) 711-718
11. Katlama C., Carvalho M.T.M., Cooper D., DeBacker K., Lefebvre E., Pedro R., et al. July. TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: Week 24 primary efficacy analysis of POWER 1 (TMC114-C213) (2005), Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil Abstract WeOaLB0102
12. Kempf D.J., King M.S., Bernstein B., Cernohous P., Bauer E., Moseley J., et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. Journal of Infectious Diseases 189 (2004) 51-60
13. Lalezari J., Thompson M., Kumar P., Piliero P., Davey R., Murtaugh T., et al. October. 873140, a novel CCR5 antagonist: antiviral activity and safety during short-term monotherapy in HIV-infected adults (2004), Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC Abstract H-1137b
14. Ledergerber B., Egger M., Opravil O., Telenti A., Hirschel B., and Battegay M. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. The Lancet 353 (1999) 863-868
15. Malan N., Krantz E., David N., Kastango K., Frederick D., Matthew M., et al. February. Efficacy and safety of atazanavir-based therapy in antiretroviral naïve HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089 (2006), 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO Abstract 107LB
16. Murphy R.L., Sanne I., Cahn P., Phanuphak P., Percival L., Kelleher T., et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 17 (2003) 2603-2614
17. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 338 (1998) 853-860
18. Porter K., Babiker A., Bhaskaran K., Darbyshire J., Pezzotti P., Porter K., et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. The Lancet 362 (2003) 1267-1274
19. Raffi F., Katlama C., Saag M., Wilkinson M., Chung J., Smiley L., et al. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus optimized regimen only (TORO) trials. Clinical Infectious Diseases 42 (2006) 870-877
20. Sanne I., Mommeja-Marin H., Hinkle J., Bartlett J.A., Lederman M.M., Maartens G., et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. Journal of Infectious Diseases 191 (2005) 825-829
21. Squires K., Lazzarin A., Gatell J.M., Powderly W.G., Pokrovskiy V., Delfraissey J.F., et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. Journal of Acquired Immune Deficiency Syndromes 36 (2004) 1011-1019
22. Tibotec Therapeutics, Division of Ortho Biotech Products, L.P. Prezista prescribing information (2006), Author, Raritan, NJ
23. van Leth F., Phanuphak P., Ruxrungtham K., Baraldi E., Miller S., Gazzard B., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN study. The Lancet 363 (2004) 1253-1263
24. Walmsley S., Bernstein B., King M., Arribas J., Beall G., Ruane P., et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New England Journal of Medicine 346 (2002) 2039-2046
25. Wilkin T., Haubrich R., Steinhart C.R., Becker S., Conant M.A., Vangeneugden T., et al. December. TMC114/r superior to standard of care in 3-class-experienced patients: 24-wks primary analysis of the POWER 2 study (TMC114-C202) (2005), 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC Abstract 2860